Articles tagged with Lung Cancer
Researchers discovered that lung cancer in younger patients has distinct genetic subtypes that can be treated with available targeted therapies. However, these patients' survival times are shorter than expected due to the more aggressive nature of the disease.
The authors propose that lethal drugs' physical consequences should be listed as immediate cause of death and underlying condition as preceding antecedent cause. Harmonization with vital statistics registrars is crucial for consistency across provinces and territories.
Researchers in Taiwan have identified a biomarker called Huntingtin interaction protein-1 (HIP1) that detects the most common type of lung cancer in its earliest stage. HIP1 expression was found to be associated with longer survival rates and reduced metastasis, suggesting its potential as a prognostic biomarker.
A new study found that women with subsolid lung nodules have a higher risk of developing lung cancer than men. The study, which reviewed CT scans from the National Lung Screening Trial, discovered that women with ground-glass nodules had a significantly higher relative risk of lung cancer.
Researchers found p53 blocks PDL1 protein, which halts immune attack on lung cancer cells. High levels of p53 and miR-34a increase survival rates in patients with lung cancer.
Researchers at Georgia State University developed a new imaging agent, ProCA1.GRPR, which effectively traces changes in cancers and targets diseased cells without radiation limitations. The agent demonstrates strong tumor penetration and shows promise for improved cancer diagnosis and treatment outcomes.
Early-stage non-small cell lung cancer patients receive varying levels of curative-intent surgery across US states, with disparities seen by race and socioeconomic factors. The study found that Massachusetts had the highest rates of curative surgery, while Wyoming had the lowest rate at 25%.
A phase III trial showed that sorafenib modestly increased progression-free survival (PFS) and disease control rate in NSCLC patients, but did not impact overall survival. The study also found that EGFR mutation positive patients receiving sorafenib had significantly longer OS and PFS.
Scientists at the Salk Institute have discovered a molecule called EphA2 that stifles aggressive growth of common and deadly type of lung cancer in humans. The enzyme normally polices tissue growth but when mutated, cellular systems can run amok, leading to tumors.
Research found that average survival was less than six months, with only 36% surviving beyond one year. Patients diagnosed through emergency routes tend to have more advanced cancers, contributing to a poorer prognosis. The study highlights the importance of early diagnosis in improving cancer survival rates.
The NRG Oncology/RTOG 0813 trial found SBRT to be well-tolerated in early-stage, centrally located non-small cell lung cancer patients. The highest dose level allowed by the protocol was reached without significant toxicity.
Researchers discovered that lung cancer cells switch to using amino acid glutamine when glucose is scarce, allowing them to continue growing under starvation conditions. Blocking this enzyme PEPCK could slow tumor growth in mice, suggesting a promising new approach to treating non-small cell lung cancer.
Research finds that 43% of patients experience heightened emotional distress before LDCT screening, with one-third experiencing ongoing distress after results are released. Distress monitoring and clinical intervention are crucial for supporting the well-being of patients undergoing lung cancer screening.
Current 20- to 29-pack-year smokers are at similar risk for lung cancer as 30+ pack-year former smokers who meet current guidelines. The study's findings suggest caution when recommending LDCT screening to this group due to untested assumptions and potential harms.
A study published by the University of Texas M. D. Anderson Cancer Center found that intensity modulated radiation therapy (IMRT) reduced severe pneumonitis and improved chemotherapy tolerance in patients with locally advanced non-small cell lung cancer compared to conventional radiation therapy.
Research reveals high rates of often preventable cancers among Indigenous populations in Australia, New Zealand, Canada, and the USA. These include lung, cervical cancer, with a significant impact from tobacco use. The study emphasizes the need for targeted prevention strategies to address cancer inequities.
A new scoring system for a common lung cancer diagnostic test has been developed, allowing physicians to more accurately assess the risk of malignancy. The EBUS-TBFNA procedure provides an accurate positive diagnosis of lung cancer 84% of the time and an accurate negative diagnosis of 68%.
The International Association for the Study of Lung Cancer (IASLC) has appointed Elsevier as the new publisher of its official journal, Journal of Thoracic Oncology. This partnership aims to enhance the journal's reputation and influence while expanding its global communities of contributors and readers.
A study of 1533 cancer survivors revealed poor adherence to dietary guidelines, with lower intakes of fiber, vitamins, and minerals, but higher intakes of empty calories. Diet quality improved with age and education level.
Research at Sahlgrenska Academy found that antioxidants double the rate of metastasis in malignant melanoma, a type of skin cancer. The study's findings contradict previous assumptions that antioxidants protect against cancer and suggest patients with cancer or an elevated risk should avoid nutritional supplements containing antioxidants.
The journal published a Special Focus issue documenting advancements in oncology since its debut in 2005. Review articles cover topics such as immunotherapy and stereotactic body radiotherapy, providing insights into the latest scientific and clinical issues in cancer research.
A Binghamton University biochemist has discovered a method to fight cancer by attacking only cancer cells and potentially reducing side effects. Hedgehogs, which normally turn off in mature cells, somehow re-activate in certain cancers, leading to uncontrolled cell growth.
A genetic polymorphism in the EPAS1 gene has been associated with poor prognosis and enhanced expression in patients with non-small cell lung cancer. The study found that individuals with the A allele had a significantly shorter overall survival time compared to those with the G allele.
The American College of Physicians recommends against routine pelvic exams for asymptomatic adult women due to low diagnostic accuracy. In contrast, the American College of Obstetrics and Gynecology maintains that annual exams are necessary for recognizing issues like incontinence and sexual dysfunction.
A study by Helmholtz Munich found that lung cancer patients incur an average of €20,000 in costs over three years. Surgery proved to be the most cost-effective treatment option, while chemotherapy and radiation therapy were more expensive.
A study of 47,000 patients found that nearly a third received more than 25 radiation treatments, despite guidelines recommending no more than 15. Privately insured patients were 40% more likely to be overtreated, highlighting the need for education and financial transparency.
The CheckMate 057 trial shows that nivolumab improves overall and 12-month survival rates compared to docetaxel in non-squamous non-small cell lung cancer patients. Nivolumab also demonstrated better patient-reported outcomes, including quality of life and slower disease deterioration.
Researchers identified distinct characteristics among non-smoking patients with NSCLC, such as lower chronic obstructive pulmonary disease and heart disease rates. Non-smokers also exhibited longer survival periods after diagnosis compared to smokers.
Patients with recurrent lung cancer who undergo a CT-based follow-up program after surgery experience significantly improved post-surgery survival rates. The study analyzed 391 patients and found that the number of patients alive four years after surgery increased from 54% to an estimated 68%.
Researchers discovered genetic changes in premalignant lung lesions that occurred before cancerous growth, detectable in blood samples. The findings suggest that circulating DNA can be used to identify patients at risk of developing lung cancer, enabling early intervention and potentially improving treatment outcomes.
According to a comprehensive report by the American Cancer Society, cancer is the second leading cause of death overall in the US, but it remains the leading cause of death among US Hispanics. Lung cancer is the primary concern, particularly for Hispanic men, who are more likely to die from this disease.
A multidisciplinary team is designing a mathematical model for autophagy in lung cancer to develop novel cancer treatment strategies. The model will be used to systematically evaluate therapeutic strategies and identify the most promising ones, which can then be evaluated experimentally.
A University of Colorado Cancer Center study found that 41% of open lung cancer clinical trials excluded patients with previously treated CNS disease, while 26% allowed those with untreated CNS involvement. The study suggests that current practice may be based on habit rather than scientific rationale.
The International Association for the Study of Lung Cancer has released new data for the TNM classification of lung cancer, which will inform the Eighth Edition of the staging manual. The new database includes 94,708 patients diagnosed worldwide from 1999-2010 and analyzes tumor size, lymph node involvement, and metastatic status.
The new 2015 WHO Classification of Lung Tumors provides standard criteria for pathology diagnosis and clinical practice. The updated classification focuses on histologic subtyping and classification according to predominant subtype, leading to multiple new discoveries in lung adenocarcinoma.
A CTCA study found that the lung microbiome diversity in patients with lung cancer was characterized by a significant presence of Streptococcaceae family bacteria. This discovery may lead to new pharmacological cancer prevention strategies and improved treatment outcomes for lung cancer patients.
A University of Colorado Cancer Center study identified a specific ratio of MET to centromere 7 that defines patients with MET-driven lung cancer susceptible to crizotinib treatment. This threshold has been associated with responses approaching 70 percent in clinical trials.
The International Association for the Study of Lung Cancer (IASLC) has issued a new statement on tobacco control and smoking cessation, calling for increased taxes on tobacco products to reduce cigarette smoking. The organization also emphasizes comprehensive advertising and promotion bans and product regulation, including pack warnings.
Men in China face increasing tobacco-related cancer risks due to high cigarette smoking rates among teenagers and continued use in adulthood. The country now produces and consumes nearly 40% of the world's cigarettes, primarily driven by men's smoking habits.
A nine-gene molecular prognostic index (MPI) provides accurate survival stratification for early-stage non-small cell lung cancer (NSCLC) patients. The MPI combines gene expression profiles with clinical data from a large database, enabling robust and clinically applicable predictions.
A study by UC Davis researchers has identified two biomarkers that can detect lung cancer up to six months before diagnosis, with an 80% accuracy rate. The findings offer a promising alternative to expensive low-dose CT scans, which involve X-ray radiation.
The International Association for the Study of Lung Cancer (IASLC) has selected 5 advocates to attend the 16th World Conference on Lung Cancer, where they will share and learn strategies to increase awareness. The recipients include Hildreth Grossman, Kathleen Mewhiney, Victor Lasebikan, Seda Kansu, and Tetsuya Yamaoka.
A recent study published in The Annals of Thoracic Surgery found that patients with suspected lung cancer often wait too long to receive treatment and skip vital diagnostic steps. Only 1 in 10 patients had the recommended combination of three staging tests before surgery, highlighting the need for improved quality care.
A study found a significant association between long telomere length and increased risk of lung adenocarcinoma. Long telomeres were associated with more rounds of cell division, potentially allowing for more opportunities to accumulate carcinogenic mutations.
Researchers discovered a small RNA molecule called miR-148a plays a role in lung cancer resistance to TRAIL, and inhibiting NF-κB makes it more effective. This study suggests a way to overcome resistance and develop new treatments for lung cancer.
A comprehensive lung cancer screening program utilizing CT scan technology at Intermountain Medical Center has been developed to detect lung cancer more accurately. The program, based on the National Lung Screening Trial, showed patients with CT scans had a 15-20% lower risk of dying compared to those with standard chest X-rays.
Researchers use light therapy glasses to trigger neurotransmitters and reset sleep cycles in lung cancer patients. Studies found that 50-80% of lung cancer patients experience severe insomnia, which can persist for eight years after diagnosis.
A new study found annual low-dose CT screening to be safe and effective for identifying pre-cancerous lung nodules. The study identified cases of cancer in participants with nonsolid lung nodules, which can progress to invasive cancer.
A new study published in Radiology found that annual low-dose computed tomography (CT) screening can safely monitor people with nonsolid lung nodules, reducing the need for unnecessary surgery and additional imaging. Nonsolid nodules are visible on CT scans of the chest and management is challenging.
A new study finds that providing direct assistance, such as counseling and nicotine replacement therapy, significantly improves the likelihood of patients quitting smoking. The research team analyzed data from over 1,600 participants who underwent lung cancer screening, finding that active clinician support increased quit rates by 40%.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that lung cancer patients with comorbidities such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death. These patients also experienced poorer survival rates at each stage of the disease.
A new technique combines dynamic PET imaging with parametric tumor mapping to detect tumors and metastases throughout the body, providing quantitative evaluation and improved contrast. This method has the potential to be used for early diagnosis and more accurate prognosis of various cancers.
Researchers at The Wistar Institute have identified a protein biomarker AKAP4 that appears to be more accurate in detecting non-small cell lung cancer. This discovery could lead to the development of a simple blood test for annual screening, potentially saving lives by detecting the disease earlier.
Researchers at the Weizmann Institute have developed a three-pronged approach to prevent lung cancer cells from developing resistance to chemotherapy. The new strategy involves targeting two main growth receptor siblings, HER2 and HER3, in addition to an existing anti-EGFR antibody.
The global burden of disease study estimated 14.9 million new cancer cases and 8.2 million deaths in 2013. Lung and breast cancers were the leading causes of cancer-related deaths, with tracheal bronchus and lung cancer being the most common among men.
Researchers at Winship Cancer Institute of Emory University have discovered a novel strategy to exploit apoptosis in lung cancer treatment by inhibiting the Bcl-2 protein. A new class of compounds has been identified that bind to the BH4 domain of Bcl-2, promoting cancer cell death.
A study found that 38% of lung cancer survivors developed recurrent or new cancer during a 8.3-year surveillance period. Key risk factors for recurrence included smoking status, prior cancers, and asbestos exposure, highlighting the need for close monitoring and quitting smoking to reduce cancer recurrence.
Researchers at Johns Hopkins Medicine have designed a molecule called RK-33 to target the enzyme DDX3, which is overexpressed in over 90% of lung cancer samples. The therapy has shown promising results in mice, with the ability to lower radiation doses while increasing its effectiveness.
Researchers found that adding genetic information to a smoker's clinical risk profile results in improved lung cancer screening adherence, with higher-risk individuals more likely to adhere to follow-up CT scans. The study suggests that gene-based risk assessment can improve screening compliance and reduce the need for reclassification.
A new genomic test has been validated for detecting lung cancer with high sensitivity, allowing physicians to identify patients at low probability of having the disease. This test can spare patients from costly and risky procedures, improving diagnosis and patient anxiety.